← brief for 2026-11-03 · Slowing decline

Writing and Amending the Clinical Protocol: IND and CTA Lifecycle Strategy for B-Cell Activating Factor and APRIL-Targeted Biologics in IgA Nephropathy

Article No results yet Not peer reviewed

Key takeaways

This article explains how to plan a clinical trial for a new kidney drug. It focuses on the paperwork and strategy for testing the drug. There are no patient results yet.

Who did this work

Yemurayi Hungwe · Perpetua Ulofu · Precious Sunday · Uchechukwu Veronica Ikechukwu · Peivand Pirouzi (Seneca Polytechnic)

Source

Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-11-02
https://doi.org/10.5281/zenodo.23891172